1. Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr. 2017;8(2):240-52. doi:10.3945/an.116.013151

2. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019; 70(3): 531-44. doi:10.1016/j.jhep.2018.10.033

3. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99(3): 535-42. doi:10.3945/ajcn.113.068890

4. Foschi FG, Bedogni G, Domenicali M, Giacomoni P, Dall'Aglio AC, Dazzani F, et al. Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterol. 2018; 18(1): 177. doi:10.1186/s12876-018-0906-8

5. Sharifi N, Amani R, Hajiani E, Cheraghian B. Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Exp Biol Med (Maywood). 2016;241 (8):830-8. doi:10.1177/1535370216629009

6. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. doi:10.1016/j.jhep.2014.12.012

7. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65(8): 1038-48. doi:10.1016/j.metabol.2015.12.012

8. Darand M, Alavian SM, Hekmatdoost A. Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence. Hepat Mon. 2018; 18(10): e68046. doi:10.5812/hepatmon.68046

9. Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, et al. How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Hepat Mon. 2013; 13(12): e15227. doi:10.5812/hepatmon.15227

10. Noori M, Jafari B, Hekmatdoost A. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. J Sci Food Agric. 2017; 97(8): 2327-32. doi:10.1002/jsfa.8042

11. Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol. 2015; 7(25): 2597-602. doi:10.4254/wjh.v7.i25.2597

12. Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016; 16(1): e34897. doi:10.5812/hepatmon.34897

13. Talari HR, Molaqanbari MR, Mokfi M, Taghizadeh M, Bahmani F, Tabatabaei SMH, et al. The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial. Sci Rep. 2022;12(1):14047. doi:10.1038/s41598-022-18195-8

14. Sharifi N, Amani R. Vitamin D supplementation and non-alcoholic fatty liver disease: A critical and systematic review of clinical trials. Crit Rev Food Sci Nutr. 2019;59(4):693-703. doi:10.1080/10408398.2017.1389693

15. Sharifi N, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014; 47(1): 70-80.doi:10.1007/s12020-014-0336-5

16. Mohtashamian A, Ebrahimzadeh A, Shamekhi Z, Sharifi N. Nigella sativa supplementation and non-alcoholic fatty liver disease: A systematic review of clinical trials. Avicenna J Phytomed. 2023;13(1):18-33.

17. Fuloria S, Mehta J, Chandel A, Sekar M, Rani N, Begum MY, et al. A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin. Front Pharmacol. 2022;13:820806.doi:10.3389/fphar.2022.820806

18. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. J Diet Suppl. 2016;13 (2): 209-20. doi:10.3109/19390211.2015.1008611

19. Alm-Eldeen AA, Mona MH, Shati AA, El-Mekkawy HI. Synergistic effect of black tea and curcumin in improving the hepatotoxicity induced by aflatoxin B1 in rats. Toxicol Ind Health. 2015;31 (12):1269-80. doi:10.1177/0748233713491807

20. Dattani JJ, Rajput DK, Moid N, Highland HN, George LB, Desai KR. Ameliorative effect of curcumin on hepatotoxicity induced by chloroquine phosphate. Environ Toxicol Pharmacol. 2010;30(2): 103-9. doi:10.1016/j.etap.2010.04.001

21. Coban D, Milenkovic D, Chanet A, Khallou-Laschet J, Sabbe L, Palagani A, et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res. 2012;56(8):1270-81. doi:10.1002/mnfr.201100818

22. Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004;41(6):926-34. doi:10.1016/j.jhep.2004.08.010

23. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res. 2016;30(9):1540-8. doi:10.1002/ptr.5659

24. Kocher A, Bohnert L, Schiborr C, Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016; 60(7): 1555-63. doi:10.1002/mnfr.201501034

25. Ganjali S, Sahebkar A, Mahdipour E, Jamialahmadi K, Torabi S, Akhlaghi S, et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal. 2014; 2014: 898361. doi:10.1155/2014/898361

26. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis. 2015;16(10):541-57. doi:10.1111/1751-2980.12291

27. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145-71. doi:10.1146/annurev-pathol-121808-102132

28. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691-701. doi:10.1038/nrgastro.2010.172

29. 29. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010; 51(2): 373-5. doi:10.1002/hep.23521

30. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010; 51(2): 595-602. doi:10.1002/hep.23314

31. Zhou Y, Llaurado G, Oresic M, Hyotylainen T, Orho-Melander M, Yki-Jarvinen H. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J Hepatol. 2015;62(3):657-63. doi:10.1016/j.jhep.2014.10.010

32. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1389-97. doi:10.1002/hep.25539

33. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120(5): 1183-92. doi:10.1053/gast.2001.23256

34. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35(2):367-72. doi:10.1053/jhep.2002.30690

35. Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology. 2014;146(1):46-62. doi:10.1053/j.gastro.2013.11.001

36. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013; 28 Suppl 1:68-76. doi:10.1111/jgh.12212

37. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998; 114(4): 842-5.doi:10.1016/S0016-5085(98)70599-2

38. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114(4):764-74. doi:10.1016/S0016-5085(98)70590-6

39. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5): 1836-46. doi:10.1002/hep.24001

40. Urošević M, Nikolić L, Gajić I, Nikolić V, Dinić A, Miljković V. Curcumin: Biological Activities and Modern Pharmaceutical Forms. Antibiotics (Basel). 2022;11(2). doi:10.3390/antibiotics11020135

41. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283-99. doi:10.1111/j.1440-1681.2011.05648.x

42. Siviero A, Gallo E, Maggini V, Gori L, Mugelli A, Firenzuoli F, et al. Curcumin, a golden spice with a low bioavailability. J Herbal Med. 2015; 5(2): 57-70. doi:10.1016/j.hermed.2015.03.001

43. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo M, Gonzalez-Vergara E, Rojas-Hernandez A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim Acta A Mol Biomol Spectrosc. 2004;60(5):1091-7. doi:10.1016/S1386-1425(03)00342-1

44. Jayaprakasha GK, Jaganmohan Rao L, Sakariah KK. Antioxidant activities of curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food Chem. 2006; 98(4): 720-4. doi:10.1016/j.foodchem.2005.06.037

45. Galano A, Álvarez-Diduk R, Ramírez-Silva MT, Alarcón-Ángeles G, Rojas-Hernández A. Role of the reacting free radicals on the antioxidant mechanism of curcumin. Chem Physics. 2009; 363(1): 13-23. doi:10.1016/j.chemphys.2009.07.003

46. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Res (Stuttg). 2017;67(4):244-51. doi:10.1055/s-0043-100019

47. Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M. Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases. J Am Coll Nutr. 2017; 36(4): 261-7. doi:10.1080/07315724.2016.1267597

48. Chirapongsathorn S, Jearjesdakul J, Sanpajit T, Juthaputthi A, editors. Curcumin trend to improve alanine transaminase (ALT) in non-alcoholic fatty liver disease (NAFLD) with abnormal ALT. Journal of Gastroenterology and Hepatology; 2012: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.

49. Wei Z, Liu N, Tantai X, Xing X, Xiao C, Chen L, et al. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Hepatol Int. 2019; 13(3): 302-13. doi:10.1007/s12072-018-9910-x

50. Panahi Y, Kianpour P, Mohtashami R, Soflaei SS, Sahebkar A. Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a clinical study. J Asian Nat Prod Res. 2019; 21(8): 798-805. doi:10.1080/10286020.2018.1505873

51. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017; 9(16): 715-32. doi:10.4254/wjh.v9.i16.715

52. Lobo R, Prabhu KS, Shirwaikar A, Shirwaikar A. Curcuma zedoaria Rosc. (white turmeric): a review of its chemical, pharmacological and ethnomedicinal properties. J Pharm Pharmacol. 2009; 61(1): 13-21. doi:10.1211/jpp/61.01.0003

53. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-57. doi:10.1002/hep.29367

54. Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, et al. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. BMJ Open. 2017; 7(7): e016914. doi:10.1136/bmjopen-2017-016914